What is Zacks Research's Forecast for GSK Q1 Earnings?

GSK plc (NYSE:GSK - Free Report) - Research analysts at Zacks Research lowered their Q1 2026 EPS estimates for GSK in a report released on Wednesday, October 16th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings per share of $1.11 for the quarter, down from their previous forecast of $1.12. The consensus estimate for GSK's current full-year earnings is $4.14 per share.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The business had revenue of $9.95 billion during the quarter, compared to analysts' expectations of $9.49 billion.

A number of other research firms have also recently weighed in on GSK. Citigroup raised shares of GSK to a "strong-buy" rating in a report on Monday, June 24th. Barclays raised GSK to a "hold" rating in a report on Tuesday, August 27th. Berenberg Bank raised GSK to a "strong-buy" rating in a research report on Thursday, June 20th. UBS Group lowered shares of GSK from a "buy" rating to a "neutral" rating in a research report on Monday, July 8th. Finally, Argus upgraded shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $50.00.

GSK Stock Down 1.1 %

Shares of GSK traded down $0.43 during mid-day trading on Friday, reaching $38.54. The company's stock had a trading volume of 3,728,100 shares, compared to its average volume of 3,740,418. The company's 50 day moving average is $41.47 and its 200 day moving average is $41.28. The stock has a market cap of $79.86 billion, a PE ratio of 14.12, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. GSK has a 12-month low of $33.67 and a 12-month high of $45.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were given a $0.3843 dividend. The ex-dividend date was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a yield of 3.99%. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio (DPR) is presently 55.80%.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 10.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GSK

Several institutional investors have recently modified their holdings of GSK. 1832 Asset Management L.P. increased its holdings in GSK by 9.1% during the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company's stock valued at $132,000 after acquiring an additional 257 shares in the last quarter. Boltwood Capital Management lifted its stake in GSK by 2.5% in the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company's stock valued at $429,000 after buying an additional 270 shares in the last quarter. J.W. Cole Advisors Inc. grew its holdings in GSK by 4.7% during the 1st quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company's stock valued at $261,000 after buying an additional 271 shares during the last quarter. First Affirmative Financial Network increased its position in GSK by 4.7% during the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company's stock worth $245,000 after buying an additional 283 shares in the last quarter. Finally, Chapin Davis Inc. lifted its position in shares of GSK by 2.2% in the first quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company's stock valued at $610,000 after acquiring an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.